LY 191704
LY 191704 Basic information
- Product Name:
- LY 191704
- Synonyms:
-
- LY 191704
- Benzo[f]quinolin-3(2H)-one, 8-chloro-1,4,4a,5,6,10b-hexahydro-4-methyl-, (4aR,10bR)-rel-
- CAS:
- 146117-78-4
- MF:
- C14H16ClNO
- MW:
- 249.74
- Mol File:
- 146117-78-4.mol
LY 191704 Usage And Synthesis
Description
LY 191704 is a 5α-reductase type 1 inhibitor that has potential for the treatment of disorders associated with the overproduction of dihydrotestosterone such as androgenetic alopecia and prostatic hyperplasia. LY 191704 also has potential in the treatment of acne.
Uses
LY191704, as a benzoquinolinone, is a potent, nonsteroidal, noncompetitive and selective human type I 5α-reductase inhibitor. LY191704 is a racemic mixture of the compounds LY300502 and LY300503. LY191704 may be useful in the research of human endocrine disorders associated with overproduction of dihydrotestosterone (DHT) by 5α-reductase type 1[1][2].
in vivo
LY191704 (10, 30, or 100 mg/kg; p.o.; 1 month) increases plasma concentrations[1].
| Animal Model: | Rats[1] |
| Dosage: | 10, 30, or 100 mg/kg |
| Administration: | P.o.; 1 month |
| Result: | Increased plasma concentrations. |
References
[1] Farid NA, et al. Stereoselective disposition of the enantiomers of the benzoquinolinone LY191704, a human type I 5 alpha-reductase inhibitor. Differences between rats and dogs. Drug Metab Dispos. 1996;24(10):1162-1165. PMID:8894520
[2] Hirsch KS, et al. LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1. Proc Natl Acad Sci U S A. 1993;90(11):5277-5281. DOI:10.1073/pnas.90.11.5277